SOLTF - Sosei Group Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

Sosei Group Corporation

PMO Hanzomon
11th Floor 2-1 Kojimachi Chiyoda-ku
Tokyo 102-0083
81 3 5210 3290

Full Time Employees202

Key Executives

NameTitlePayExercisedYear Born
Mr. Shinichi TamuraFounder & Chairman2.36MN/A1949
Mr. Chris CargillRepresentative Exec. Officer, Pres, CEO & Director1.66MN/A1984
Mr. Hironoshin NomuraSr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFON/AN/AN/A
Mr. Kieran Johnson F.C.A.Exec. Officer, VP & Chief Accounting OfficerN/AN/AN/A
Dr. Miles CongreveChief Scientific OfficerN/AN/AN/A
Mr. Kazuhiko YoshizumiExec. Officer, VP & Chief Compliance OfficerN/AN/A1954
Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresN/AN/AN/A
Stacey SouthallAssociate Director & Head of BiophysicsN/AN/AN/A
Ms. Candelle ChongExec. Officer, Exec. VP & Chief of StaffN/AN/AN/A
Dr. Matt BarnesHead of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&DN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Corporate Governance

Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.